We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

31 hedge funds and large institutions have $18.7M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more capital invested

Capital invested by funds: $11.9M → $18.7M (+$6.8M)

11% less funds holding

Funds holding: 35 → 31 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
6
Reduced
12
Closed
12
Calls
$16K
Puts
–
Net Calls
+$16K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
ACM
Athyrium Capital Management
New York
+$13.2M
2
RA
Rovida Advisors
Florida
+$3.95M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.83M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$1.62M
5
Renaissance Technologies
Renaissance Technologies
New York
+$712K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$136K
2
E
Ergoteles
New York
-$122K
3
Morgan Stanley
Morgan Stanley
New York
-$92.1K
4
Goldman Sachs
Goldman Sachs
New York
-$80K
5
HF
HRT Financial
New York
-$67K
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
26
Huntington National Bank
Ohio
$2K +$2.68K +1,650 New
Simplex Trading
27
Simplex Trading
Illinois
$2K +$3.73K +2,298 New
Osaic Holdings
28
Osaic Holdings
Arizona
$1K -$811 -500 -30%
PNC Financial Services Group
29
PNC Financial Services Group
Pennsylvania
$1K – – –
E
30
Ergoteles
New York
– -$122K -41,349 Closed
Goldman Sachs
31
Goldman Sachs
New York
– -$80K -27,120 Closed
HF
32
HRT Financial
New York
– -$67K -22,866 Closed
ProShare Advisors
33
ProShare Advisors
Maryland
– -$40K -13,434 Closed
NFG
34
Nations Financial Group
Iowa
– -$37K -12,500 Closed
Walleye Trading
35
Walleye Trading
New York
– -$30K -10,000 Closed
Bank of America
36
Bank of America
North Carolina
– -$10.1K -6,213 -100%
JP Morgan Chase
37
JP Morgan Chase
New York
– -$6.9K -4,250 -100%
Citigroup
38
Citigroup
New York
– -$10K -3,526 Closed
Barclays
39
Barclays
United Kingdom
– -$7K -2,425 Closed
PCM
40
Penserra Capital Management
California
– -$4K -1,440 Closed
OSAM
41
O'Shaughnessy Asset Management
Connecticut
– -$4K -1,299 Closed
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
– -$127 -43 Closed
1
2

RVLP Hedge Fund Activity: Q4 2021 in Review

31 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2021, worth a combined $18.7M — up 57% from $11.9M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of RVLP and 8 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Athyrium Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Millennium Management, cutting an estimated $136K.

  • 31 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2021, down from 35 in Q3 2021.
  • Funds reported $18.7M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2021, up 57% quarter-over-quarter.
  • 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2021 and 12 closed out, a net change of -4 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2021 was Athyrium Capital Management, an estimated $13.2M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2021 was Millennium Management, an estimated $136K sold.

Based on aggregated 13F filings for Q4 2021.